Headquartered in North Bethesda, Maryland, Ibex Biosciences, Inc. ("Ibex") distinguishes itself in the early-stage biotech sector with its varied research and development approach.

Ibex is committed to discovering, validating, and developing potential health solutions through investment in unconventional projects and methodologies, irrespective of their recognition within the broader research community.

Ibex boasts a diverse portfolio that includes therapeutic antibodies, gene therapies, and regenerative medicine programs.

We are proud of our proven capacity to discover and validate potential therapies from scratch, thus eliminating the need for external technology acquisitions or in-licensing.

Our accomplishments are underscored by a series of in vivo studies, which have delivered remarkable efficacy against a range of challenging medical conditions.

Ibex Announces New Patent Pending

Ibex announces the publication of its patent application for antibodies targeting CD147, including ADCs

Ibex Biosciences was awarded as a Top 10 Biotech Startup

Ibex was recognized as an Innovative Biotech Company

Research & Development

Highlights